Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: The VOICE-C qualitative study in Johannesburg, South Africa

Journal of the International AIDS Society

Volumn 17, Issue 3, 2014, Pages

  Van Der Straten, Ariane ^a,b   Stadler, Jonathan ^c   Luecke, Ellen ^a   Laborde, Nicole ^a   Hartmann, Miriam ^a   Montgomery, Elizabeth T ^a  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Adherence; Antiretroviral; HIV prevention; HIV stigma; Microbicides; Pre exposure prophylaxis; Qualitative methods; South Africa

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MICROBICIDE; TENOFOVIR;

ADULT; ARTICLE; COMMUNITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ETHNOGRAPHY; FEMALE; HEALTH; HOUSEHOLD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PRE EXPOSURE PROPHYLAXIS; PROPHYLAXIS; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; STIGMA; WORKPLACE; CHEMOPROPHYLAXIS; DISEASE TRANSMISSION; HIV INFECTIONS; INTRAVAGINAL DRUG ADMINISTRATION; MEDICATION COMPLIANCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT ATTITUDE; PRE-EXPOSURE PROPHYLAXIS; PREVENTION AND CONTROL; PROCEDURES; PSYCHOLOGY; YOUNG ADULT;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADULT; ANTI-RETROVIRAL AGENTS; CHEMOPREVENTION; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PRE-EXPOSURE PROPHYLAXIS; SOUTH AFRICA; YOUNG ADULT;

EID: 84916230041     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.17.3.19146     Document Type: Article

References (38)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99
2. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410
3. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2012 :1-12
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):411-22
5. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883): 2083-90
6. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Preexposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofoviremtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). CROI; 2013 Mar 3-6; Atlanta, GA; 2013
7. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13-F19. doi: 10.1097/QAD.0b013e3283522272
8. Baeten J, Celum C. Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS. 2012;7(6):514-9
9. Baeten J, Celum C. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med. 2013; 64:219-32
10. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74
11. Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2012;17(6):2162-72
12. Minnis AM, Gandham S, Richardson BA, Guddera V, Chen B, Salata R, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17(2):737-47
13. Muchomba FM, Gearing RE, Simoni JM, El-Bassel N. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012;61(4):490-8
14. Tangmunkongvorakul A, Chariyalertsak S, Amico KR, Saokhieo P, Wannalak V, Sangangamsakun T, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013;25(8):961-7
15. Amico KR, Liu A, McMahan V, Anderson PL, Lama JR, Guanira J, et al., editors. Adherence indicators and pre-exposure prophylaxis (PrEP) drug levels in the iPrEx study. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA; Feb 27-Mar 2, 2011
16. Ammassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: the role of adherence in the late HAART era. Antiviral Ther. 2012;17(5):785-92
17. Munakata J, Benner JS, Becker S, Dezii CM, Hazard EH, Tierce JC. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. Med Care. 2006;44(10):893-9
18. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30
19. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001; 15(16):2109-17
20. Dlamini PS, Wantland D, Makoae LN, Chirwa M, Kohi TW, Greeff M, et al. HIV stigma and missed medications in HIV-positive people in five African countries. AIDS Patient Care STDS. 2009;23(5):377-87
21. Skhosana NL, Struthers H, Gray GE, McIntyre JA. HIV disclosure and other factors that impact on adherence to antiretroviral therapy: the case of Soweto, South Africa. Afr J AIDS Res. 2006;5:17-26
22. Ware NC, Wyatt MA, Tugenberg T. Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS. AIDS Care. 2006;18(8): 904-10
23. Ambia J, Agot K. Barriers and facilitators of adherence in user- dependent HIV prevention trials, a systematic review. Int STD Res Rev. 2013;1(1):12-29
24. Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies. Am J Prev Med. 2013;44(1 Suppl 2):S91-8
25. van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One. 2014;9(2):89118
26. Microbicide trials network statement on decision to discontinue use of tenofovir gel and oral tablets in VOICE, a major HIV prevention study in women. Pittsburgh, PA: Microbicide Trials Network; 2011. Available from: http://www.mtnstopshiv.org/node/3909
27. Montgomery E, Stadler J, Hartmann M, Magee C, Magazi B, Mathebula F, et al., editors. Male partner roles and influence on women's use of HIV pre-exposure prophylaxis in Johannesburg. AIDS Impact; 2013 Sep 29-Oct 3; Barcelona, Spain; 2013
28. Grelotti DJ, Closson EF, Smit JA, Mabude Z, Matthews LT, Safren SA, et al. Whoonga: potential recreational use of HIV antiretroviral medication in South Africa. AIDS Behav. 2014;18(3):511-8
29. Niehaus IA. Death before dying: understanding AIDS stigma in the South African Lowveld. J South Afr Stud. 2007;33:845-60
30. Ashforth A, Nattrass N. Ambiguities of 'culture' and the antiretroviral rollout in South Africa. Soc Dynam. 2005;31(2):285-303
31. Goffman E. Stigma: notes on the management of spoiled identity. Saddle Hill, NJ: Prentice-Hall; 1963
32. Nyblade L, Singh S, Ashburn K, Brady L, Olenja J. "Once I begin to participate, people will run away from me": understanding stigma as a barrier to HIV vaccine research participation in Kenya. Vaccine. 2011;29(48):8924-8
33. Baeten JM, Grant R. Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep. 2013;10(2):142-51
34. Castro A, Farmer P. Understanding and addressing AIDS-related stigma: from anthropological theory to clinical practice in Haiti. Am J Public Health. 2005;95:53-9
35. Chakrapani V, Newman PA, Singhal N, Jerajani J, Shunmugam M. Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach. PLoS One. 2012;7(12):e51080
36. Abdool Karim S. Stigma impedes AIDS prevention. Nature. 2011; 474(7349):29-31
37. Schneider H, Fassin D. Denial and defiance: a socio-political analysis of AIDS in South Africa. AIDS. 2002;16:S45-51
38. Corneli A, Perry B, Agot K, Ahmed K, McKenna K, Malamatsho F, et al. FEM-PrEP: participant explanations for non-adherence. Conference on Retroviruses and Opportunistic Infections. MA: Boston; Mar 3-6, 2014